Skip to main content

Table 3 Acute toxicities in the 730 NPC patients

From: The long-term survival of patients with III-IVb stage nasopharyngeal carcinoma treated with IMRT with or without Nimotuzumab: a propensity score-matched analysis

Acute Toxicity

Nimotuzumab Arm

N = 184(%)

No Nimotuzumab Arm

N = 546

P value

Anemia

  

0.920

 G0-G1

137(74.5)

416(76.2)

 

 G2

36(19.6)

98(17.9)

 

 G3

9(4.0)

27(4.9)

 

 G4

2(1.1)

5(0.9)

 

Thrombocytopenia

  

0.541

 G0-G1

164(89.1)

464(85.0)

 

 G2

16(8.7)

58(10.6)

 

 G3

4(2.2)

21(3.8)

 

 G4

0(0.0)

3(0.5)

 

Leukopenia

  

0.845

 G0-G1

122(66.3)

370(67.8)

 

 G2

33(17.9)

101(18.5)

 

 G3

27(14.7)

7113.0()

 

 G4

2(1.1)

4(0.7)

 

Neutropenia

  

0.154

 G0-G1

139(75.5)

386(70.7)

 

 G2

39(21.2)

118(21.6)

 

 G3

5(2.7)

38(7.0)

 

 G4

1(0.5)

4(0.7)

 

Skin reaction

  

0.434

 G0-G1

126(68.5)

381(69.8)

 

 G2

46(25.0)

117(21.4)

 

 G3

12(6.5)

48(8.8)

 

Mucositis

  

0.728

 G0-G1

67(36.4)

189(34.6)

 

 G2

73(39.7)

228(41.8)

 

 G3

38(20.7)

102(18.7)

 

 G4

6(3.3)

27(4.9)

 

Nausea

  

0.394

 G0-G1

62(37.8)

193(35.3)

 

 G2

71(43.3)

214(39.2)

 

 G3

28(17.1)

126(23.1)

 

 G4

3(1.8)

13(2.4)

 

Vomiting

  

0.990

 G0-G1

138(75.0)

412(75.5)

 

 G2

24(13.0)

68(12.5)

 

 G3

20(10.9)

61(11.2)

 

 G4

2(1.1)

5(0.9)

 

Diarrhea

  

0.495

 G0-G1

146(79.3)

437(80.0)

 

 G2

31(16.8)

97(17.8)

 

 G3

7(3.8)

12(2.2)

 

Hepatotoxicity

  

0.532

 G0-G1

137(74.5)

410(75.1)

 

 G2

32(17.4)

80(14.7)

 

 G3

15(8.2)

56(10.3)

 

Nephrotoxicity

  

0.770

 G0-G1

167(90.8)

505(92.5)

 

 G2

12(6.5)

29(5.3)

 

 G3

5(2.7)

12(2.2)

 

Weight loss

  

0.964

 G0-G1

14,478.3()

420(76.9)

 

 G2

36(19.6)

112(20.5)

 

 G3

4(2.2)

14(2.6)